Recruiting Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer NCT07500298 Conditions Bevacizimab, Colonic Diseases, Colorectal Neoplasms, +15 more Locations MD Anderson Cancer Center — Houston, Texas, United States View Trial Details
Recruiting Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma NCT07324824 Conditions Adenocarcinoma, Bevacizimab, Carcinoma, +12 more Locations Sun Yat-sen University Cancer Center — Guangzhou, Guangdong, China View Trial Details
Completed Chronic Inflammation, Plasma Proteins Signature, Survival Outcomes and Clinical Response, in Patients Receiving Bevacizumab Combined With Oxaliplatin-based Chemotherapy (Bev/OX) or Bevacizumab Combined With Irinotecan-based Chemotherapy (Bev/IRI) NCT07241403 Conditions Bevacizimab, Colonic Diseases, Colorectal Cancer, +12 more Locations The second hospital of Nanchang university — Nanchang, Jiangxi, China View Trial Details
Completed Response Prediction for Anti-angiogenic Treatment in Recurrent Glioblastoma NCT04143425 Conditions Adult Glioblastoma, Astrocytoma, Bevacizimab, +10 more Locations Asan Medical Center — Seoul, South Korea View Trial Details
